Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Onxeo (Miconazole Buccal Tablets 50mg)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

North American rights to develop drug that treats side effects from cancer therapies. The rights concern Oravig, an orally-dissolving buccal tablet approved for oral thrush, an oral yeast infection that is a side effect of cancer therapy.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Primary Office
  • 49 boulevard du Général Martial Valin
  • 75015 Paris
  • France

+33 01 00 00 00 00

Onxeo (Miconazole Buccal Tablets 50mg) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Onxeo (Miconazole Buccal Tablets 50mg)‘s full profile, request access.

Request full access to PitchBook

Onxeo (Miconazole Buccal Tablets 50mg) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Onxeo (Miconazole Buccal Tablets 50mg)‘s full profile, request access.

Request full access to PitchBook